RaPiDS- A Phase 2 Study of Anti-PD-1 Independently or in Combination With Anti-CTLA-4 in Second-Line Cervical Cancer
- First Posted Date
- 2019-03-28
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Agenus Inc.
- Target Recruit Count
- 212
- Registration Number
- NCT03894215
- Locations
- 🇺🇸
UCLA- Women's Health Clinical Research Unit (WHCRU), Los Angeles, California, United States
🇺🇸The Ohio State University Wexner Medical Center, Columbus, Ohio, United States
🇺🇸Columbus NCORP, Columbus, Ohio, United States
Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer
- First Posted Date
- 2019-03-01
- Last Posted Date
- 2024-08-28
- Lead Sponsor
- Agenus Inc.
- Target Recruit Count
- 550
- Registration Number
- NCT03860272
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸University of Miami Sylvester Comprehensive Cancer Center, Miami, Florida, United States
🇺🇸Providence Portland Cancer Center, Portland, Oregon, United States
Phase 1a Study to Evaluate Immunogenicity of ASV®
- Conditions
- Interventions
- First Posted Date
- 2018-09-17
- Last Posted Date
- 2021-12-02
- Lead Sponsor
- Agenus Inc.
- Target Recruit Count
- 3
- Registration Number
- NCT03673020
- Locations
- 🇺🇸
School of Medicine at the University of Miami, Miami, Florida, United States
Subjects With Metastatic or Locally Advanced Solid Tumors, and Expansion Into Select Solid Tumors (Cervical)
- First Posted Date
- 2018-04-12
- Last Posted Date
- 2023-07-05
- Lead Sponsor
- Agenus Inc.
- Target Recruit Count
- 154
- Registration Number
- NCT03495882
- Locations
- 🇺🇸
Chattanooga's Program In Women's Oncology, Chattanooga, Tennessee, United States
🇺🇸West Michigan Cancer Center, Kalamazoo, Michigan, United States
🇺🇸University of Oklahoma, Oklahoma City, Oklahoma, United States
Study of AGEN1884 With Pembrolizumab in 1L NSCLC
- Conditions
- Interventions
- First Posted Date
- 2018-01-26
- Last Posted Date
- 2020-06-02
- Lead Sponsor
- Agenus Inc.
- Target Recruit Count
- 2
- Registration Number
- NCT03411473
- Locations
- 🇦🇺
Mater Research, Brisbane, Australia
🇦🇺Sydney Adventist, Wahroonga, Australia
🇦🇺Scientia Clinical Research, Sydney, Australia
Study of AGEN2034 in Advanced Tumors and Cervical Cancer
- First Posted Date
- 2017-04-07
- Last Posted Date
- 2023-06-05
- Lead Sponsor
- Agenus Inc.
- Target Recruit Count
- 211
- Registration Number
- NCT03104699
- Locations
- 🇺🇸
University of Southern California - Keck School of Medicine, Los Angeles, California, United States
🇺🇸Florida Cancer Specialists & Research Institute, Sarasota, Florida, United States
🇺🇸Augusta Oncology, Augusta, Georgia, United States
Safety and Tolerability Study of AutoSynVax™ Vaccine in Subjects With Advanced Cancer
- First Posted Date
- 2016-12-14
- Last Posted Date
- 2020-06-02
- Lead Sponsor
- Agenus Inc.
- Target Recruit Count
- 3
- Registration Number
- NCT02992977
- Locations
- 🇺🇸
The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
🇺🇸School of Medicine at the University of Miami, Miami, Florida, United States
AGEN1884, an Anti-CTLA-4 Human Monoclonal Antibody in Subjects With Advanced or Refractory Cancer and Who Have Progressed With PD-1/PD-L1 Inhibitor as Their Most Recent Therapy
- Conditions
- Interventions
- First Posted Date
- 2016-03-01
- Last Posted Date
- 2023-02-27
- Lead Sponsor
- Agenus Inc.
- Target Recruit Count
- 88
- Registration Number
- NCT02694822
- Locations
- 🇺🇸
Levine Cancer Institute, Charlotte, North Carolina, United States
🇺🇸The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
🇺🇸Atlantic Health System/Morristown Medical Center, Morristown, New Jersey, United States
Biological Efficacy Study of HerpV Vaccine With QS-21 to Treat Participants With Recurrent Genital Herpes
- First Posted Date
- 2012-09-19
- Last Posted Date
- 2021-07-13
- Lead Sponsor
- Agenus Inc.
- Target Recruit Count
- 80
- Registration Number
- NCT01687595
- Locations
- 🇺🇸
Center for Clinical Studies - Cypress, Houston, Texas, United States
🇺🇸Westover Heights Clinic, Portland, Oregon, United States
🇺🇸Center for Clinical Studies - Texas Medical Center, Houston, Texas, United States
Study of Vitespen (HSPPC-96, Oncophage ®) for Immune Response Assessment in Participants With Resectable Renal Cell Carcinoma at Intermediate Risk of Recurrence
- First Posted Date
- 2010-06-22
- Last Posted Date
- 2021-06-03
- Lead Sponsor
- Agenus Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT01147536
- Locations
- 🇺🇸
Community Care Physicians, Albany, New York, United States
🇨🇦Pavillion de Recherche de Hotel Dieu, Quebec, Canada
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States